Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Cortical porosity development and progression is mitigated after etelcalcetide treatment in an animal model of chronic kidney disease.

Authors:
Elizabeth A Swallow Corinne E Metzger Christopher L Newman Neal X Chen Sharon M Moe Matthew R Allen

Bone 2022 04 24;157:116340. Epub 2022 Jan 24.

Department of Anatomy, Cell Biology & Physiology, Indiana University School of Medicine, Indianapolis, IN, United States; Department of Medicine, Division of Nephrology, Indiana University School of Medicine, Indianapolis, IN, United States; Roudebush Veterans Administration Medical Center, Indianapolis, IN, United States. Electronic address:

Purpose: Chronic kidney disease (CKD) leads to increased bone fragility and risk of fracture. Cortical deteriorations, including cortical porosity, are key factors in fracture susceptibility in CKD. Since secondary hyperparathyroidism is common in CKD individuals and contributes to cortical deterioration, we hypothesized that reducing parathyroid hormone (PTH) may modulate CKD-induced cortical porosity. The goal of this pilot study was to assess the effects of lowering PTH, via the preclinical analogue of the FDA-approved calcimimetic etelcalcetide (KP-2326), on the development and progression of cortical pores in the setting of CKD.

Methods: Male Cy/+ Sprague Dawley rats with clinical biochemistries consistent with CKD (N = 8) were assigned to the study. At 30-32 weeks of age, cortical bone was assessed via In vivo μCT and blood collected for biochemistries to create baseline measures. Calcimimetic treatment with KP-2326 (KP) was then administered 3× weekly for 2-4 weeks. Cortical bone and biochemical parameters were repeated at study endpoint (33-37 wks of age). A group of age- and cohort-matched CKD rats (N = 4) were utilized as untreated controls.

Results: Untreated CKD rats had significantly increased cortical porosity over time, while porosity in KP-treated CKD rats was not significantly changed over time. Individual pore analysis revealed that pore area was significantly higher for expanding pores in untreated CKD rats compared to KP-treated CKD rats. Mechanical properties of KP-treated animal femora were similar to historical values of age-matched CKD animals and lower than those of age-matched non-diseased animals.

Conclusion: Our pilot preclinical study demonstrates that etelcalcetide treatment can mitigate the progression of cortical bone changes in an animal model of CKD through suppression of pre-existing cortical pore expansion and limiting the size of new pore development. While stabilization of porosity is beneficial it remains likely that infilling of porosity will be needed to positively affect mechanical properties of bones in the setting of CKD.

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.bone.2022.116340DOI Listing
April 2022

Publication Analysis

Top Keywords

ckd rats
20
cortical porosity
16
ckd
12
cortical bone
12
cortical
11
untreated ckd
8
progression cortical
8
kidney disease
8
chronic kidney
8
animal model
8
mechanical properties
8
etelcalcetide treatment
8
development progression
8
kp-treated ckd
8
porosity
6
rats
6
controlsresults untreated
4
study endpoint
4
endpoint 33-37
4
33-37 wks
4

Keyword Occurance

Similar Publications

Arabica coffee and olive oils mitigate malathion-induced nephrotoxicity in rat, immunohistochemical and biochemical evaluation.

Authors:
Khalid M Al-Asmari Hisham N Altayb Atef M Al-Attar Safa H Qahl Saed A Al-Thobaiti Isam M Abu Zeid

Saudi J Biol Sci 2022 Jun 13;29(6):103307. Epub 2022 May 13.

Department of Biological Sciences, Faculty of Science, King Abdulaziz University, P.O. Box 80203, Jeddah 21589, Saudi Arabia.

Malathion (MAL) is an organophosphate insecticide that disrupts the body's antioxidant system; it is one of the earliest organophosphate insecticides extensively used as dust, emulsion, and vapor control a wide variety of insect pests under different conditions. This experimentation aims to evaluate the influence of Arabica coffee oil and olive oil on MAL-induced nephrotoxicity in male rat. 6 sets bearing the same number of animals were applied to this experiment. Read More

View Article and Full-Text PDF
June 2022
Similar Publications

Calcimimetics Alter Periosteal and Perilacunar Bone Matrix Composition and Material Properties in Early Chronic Kidney Disease.

Authors:
John G Damrath Sharon M Moe Joseph M Wallace

J Bone Miner Res 2022 May 20. Epub 2022 May 20.

Indiana University-Purdue University at Indianapolis, Department of Biomedical Engineering, Indianapolis, IN.

Chronic kidney disease (CKD) affects 15% of Americans and greatly increases fracture risk due to elevated parathyroid hormone, cortical porosity, and reduced bone material quality. Calcimimetic drugs are used to lower PTH in CKD patients, but their impact on bone matrix properties remains unknown. We hypothesized that tissue-level bone quality is altered in early CKD and that calcimimetic treatment will prevent these alterations. Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Corni Fructus Alleviates UUO-Induced Renal Fibrosis via TGF-/Smad Signaling.

Authors:
Jin A Lee Mi-Rae Shin Seong-Soo Roh

Biomed Res Int 2022 6;2022:5780964. Epub 2022 May 6.

Department of Herbology, College of Korean Medicine, Daegu Haany University, 136, Sinchendong-ro, Suseong-gu, Daegu 42158, Republic of Korea.

Renal fibrosis is a type of chronic kidney disease (CKD) induced by infiltration of inflammatory cells, myofibroblast accumulation, and ECM production in the kidney. From a long time ago, Corni Fructus (CF) is known to supplement the liver and kidney with its tepid properties. In this study, we investigated the renal protective mechanism of CF, which is known to supplement the kidney, in rat model of unilateral ureteral obstruction (UUO). Read More

View Article and Full-Text PDF
May 2022
Similar Publications

Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state.

Authors:
Amit A Joharapurkar Vishal J Patel Samadhan G Kshirsagar Maulik S Patel Hardikkumar H Savsani Chetan Kajavadara Darshan Valani Mukul R Jain

Curr Res Pharmacol Drug Discov 2022 30;3:100102. Epub 2022 Apr 30.

Department of Pharmacology and Toxicology, Zydus Research Centre, Cadila Healthcare Limited, Sarkhej Bavla NH 8A, Moraiya, Ahmedabad, Gujarat, India.

Many anemic chronic kidney disease (CKD) patients are refractory to erythropoietin (EPO) effects due to inflammation, deranged iron utilization, and generation of EPO antibodies. This work assessed the effect of desidustat, an inhibitor of hypoxia inducible factor (HIF) prolyl hydroxylase (PHD), on EPO-refractory renal anemia. Sprague Dawley rats were made anemic by cisplatin (5 ​mg/kg, IP, single dose) and turpentine oil (5 ​mL/kg, SC, once a week). Read More

View Article and Full-Text PDF
April 2022
Similar Publications

Potential Therapeutic Effects of Long-Term Stem Cell Administration: Impact on the Gene Profile and Kidney Function of PKD/Mhm (Cy/+) Rats.

Authors:
Daniela Nardozi Stefania Palumbo Arif Ul Maula Khan Carsten Sticht Karen Bieback Samar Sadeghi Mark Andreas Kluth Michael Keese Norbert Gretz

J Clin Med 2022 May 5;11(9). Epub 2022 May 5.

Medical Research Center, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer, 68167 Mannheim, Germany.

Cystic kidney disease (CKD) is a heterogeneous group of genetic disorders and one of the most common causes of end-stage renal disease. Here, we investigate the potential effects of long-term human stem cell treatment on kidney function and the gene expression profile of PKD/Mhm (Cy/+) rats. Human adipose-derived stromal cells (ASC) and human skin-derived ABCB5 stromal cells (2 × 10) were infused intravenously or intraperitoneally monthly, over 6 months. Read More

View Article and Full-Text PDF
May 2022
Similar Publications
}